All articles

Daily brief

An FDA decision and a Nepal hospital proposal

The November 16 briefing separates a US drug-application decision from Chinese approvals and reports a request for support in Nepal.

By Medical2China · Video date

Three things to know

  1. The video reports that the US FDA declined to approve Summit’s ivonescimab plus chemotherapy for previously treated, EGFR-mutated advanced lung cancer.

  2. The global HARMONi trial met its progression-free survival endpoint but did not demonstrate a statistically significant overall survival benefit. Existing Chinese approvals are separate from this US decision.

  3. In Kathmandu, Nepal’s parliamentary leadership requested Chinese support to develop B.P. Koirala Memorial Cancer Hospital into a national cancer research and training institute. New funding and implementation dates remain unconfirmed.

This is a dated video briefing. Reports and availability may have changed since it was recorded; confirm current details before making plans.